Insider Selling: Repligen Co. (NASDAQ:RGEN) CEO Sells 27,566 Shares of Stock

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 27,566 shares of the stock in a transaction on Monday, September 10th. The shares were sold at an average price of $57.71, for a total transaction of $1,590,833.86. Following the transaction, the chief executive officer now owns 255,017 shares of the company’s stock, valued at approximately $14,717,031.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ RGEN traded up $1.06 during trading on Friday, reaching $54.48. 296,395 shares of the company’s stock traded hands, compared to its average volume of 308,176. Repligen Co. has a 12-month low of $29.56 and a 12-month high of $58.99. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of 78.96, a price-to-earnings-growth ratio of 4.46 and a beta of 0.69.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Repligen had a net margin of 13.49% and a return on equity of 5.05%. The firm had revenue of $47.73 million during the quarter, compared to the consensus estimate of $45.84 million. During the same quarter in the prior year, the business posted $0.20 earnings per share. The firm’s quarterly revenue was up 47.0% on a year-over-year basis. As a group, equities research analysts expect that Repligen Co. will post 0.71 earnings per share for the current year.

Several equities research analysts have recently issued reports on the stock. Janney Montgomery Scott restated a “buy” rating on shares of Repligen in a report on Thursday. Stephens raised their price target on shares of Repligen from $50.00 to $55.00 and gave the stock an “average” rating in a research note on Tuesday, July 10th. JPMorgan Chase & Co. raised their price target on shares of Repligen to $60.00 and gave the stock an “overweight” rating in a research note on Monday, September 24th. BidaskClub raised shares of Repligen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 19th. Finally, Zacks Investment Research downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $51.86.

A number of hedge funds have recently added to or reduced their stakes in the stock. United Services Automobile Association boosted its stake in Repligen by 10.1% in the 2nd quarter. United Services Automobile Association now owns 89,357 shares of the biotechnology company’s stock worth $4,203,000 after purchasing an additional 8,200 shares in the last quarter. Northern Trust Corp boosted its stake in Repligen by 5.2% in the 2nd quarter. Northern Trust Corp now owns 543,817 shares of the biotechnology company’s stock worth $25,581,000 after purchasing an additional 27,062 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Repligen by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 498,849 shares of the biotechnology company’s stock worth $23,466,000 after purchasing an additional 14,041 shares in the last quarter. Granahan Investment Management Inc. MA boosted its stake in Repligen by 12.1% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 178,159 shares of the biotechnology company’s stock worth $8,381,000 after purchasing an additional 19,230 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Repligen in the 2nd quarter worth approximately $1,628,000. Institutional investors own 92.50% of the company’s stock.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: Hedge Funds Explained

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply